Insider · CIK 0001743780

Takimoto Chris H

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001743780

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-20	ALXOALX ONCOLOGY HOLDINGS INC · Stock option (right to buy)A Award	Director	AAward	+40.4K sh	—	—	40,400
2025-01-21	ALXOALX ONCOLOGY HOLDINGS INC · Common Stock (right to buy)A Award	Director	AAward	+40.4K sh	—	—	40,400
2024-09-13	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−1,487 sh	$11.54	−$17.2K	154,331
2024-07-19	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+43.8K sh	—	—	139,568
2024-07-19	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+16.3K sh	—	—	155,818
2024-07-19	IGM Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	CHIEF MEDICAL OFFICER	DDisposition to Issuer	−150K sh	—	—	0
2024-06-14	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−1,570 sh	$7.58	−$11.9K	95,818
2024-05-15	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+3,000 sh	$5.02	+$15.1K	97,388
2024-03-14	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−2,535 sh	$10.17	−$25.8K	94,388
2024-03-13	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−2,889 sh	$9.88	−$28.5K	96,923
2024-03-12	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+46.3K sh	—	—	99,812
2024-03-12	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF MEDICAL OFFICER	AAward	+92.5K sh	—	—	92,500
2023-11-29	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−1,180 sh	$6.21	−$7,331.34	53,562
2023-05-23	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−1,244 sh	$12.30	−$15.3K	54,757
2023-05-23	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−15 sh	$13.01	−$195.075	54,742
2023-05-15	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+962 sh	$11.71	+$11.3K	56,001
2023-04-04	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+26.3K sh	—	—	55,039
2023-04-04	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF MEDICAL OFFICER	AAward	+52.5K sh	—	—	52,500
2023-03-14	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−1,768 sh	$18.73	−$33.1K	28,789
2022-12-16	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−3,492 sh	$18.77	−$65.6K	32,495
2022-12-16	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−1,938 sh	$19.36	−$37.5K	30,557
2022-11-23	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−600 sh	$21.38	−$12.8K	36,264
2022-11-23	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−277 sh	$21.99	−$6,091.618	35,987
2022-05-24	IGM Biosciences, Inc.S Sale	CHIEF MEDICAL OFFICER	SSale	−938 sh	$17.10	−$16K	36,864
2022-05-13	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+825 sh	$12.38	+$10.2K	37,802
2022-03-15	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+14.5K sh	—	—	36,977
2022-03-12	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+12.5K sh	—	—	22,500
2022-03-12	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF MEDICAL OFFICER	AAward	+75K sh	—	—	75,000
2021-11-15	IGM Biosciences, Inc.A Award	CHIEF MEDICAL OFFICER	AAward	+10K sh	—	—	10,000
2021-07-30	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF MEDICAL OFFICER	AAward	+150K sh	—	—	150,000
2020-04-07	Forty Seven, Inc.D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−3,906 sh	—	—	0
2020-04-07	Forty Seven, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−58.1K sh	—	—	0
2020-04-07	Forty Seven, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−4,570 sh	—	—	0
2020-04-07	Forty Seven, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−70.4K sh	—	—	0
2020-04-07	Forty Seven, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−44.7K sh	—	—	0
2020-04-07	Forty Seven, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−113K sh	—	—	0
2020-04-01	Forty Seven, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+49.6K sh	$2.02	+$100K	53,533
2020-04-01	Forty Seven, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+8,333 sh	$4.88	+$40.7K	61,866
2020-04-01	Forty Seven, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+7,020 sh	$5.27	+$37K	68,886
2020-04-01	Forty Seven, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+11.4K sh	$8.76	+$100K	80,304
2020-04-01	Forty Seven, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+2,797 sh	$35.75	+$100K	83,101
2020-04-01	Forty Seven, Inc.S Sale	Chief Medical Officer	SSale	−79.2K sh	$95.42	−$7.56M	3,906
2020-04-01	Forty Seven, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−49.6K sh	—	—	58,114
2020-04-01	Forty Seven, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−8,333 sh	—	—	4,570
2020-04-01	Forty Seven, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−7,020 sh	—	—	70,398
2020-04-01	Forty Seven, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−11.4K sh	—	—	44,710
2020-04-01	Forty Seven, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−2,797 sh	—	—	113,153
2019-12-13	Forty Seven, Inc.Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+116K sh	—	—	115,950
2019-12-10	Forty Seven, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+10K sh	$2.02	+$20.2K	10,000
2019-12-10	Forty Seven, Inc.S Sale	Chief Medical Officer	SSale	−10K sh	$35.00	−$350K	0

Recent filings

Accepted (ET)
Jan 214
Takimoto Chris H0001193125-26-018022
SEC(opens sec.gov)
Jan 234
Takimoto Chris H0001415889-25-001977
SEC(opens sec.gov)
Sep 174
Takimoto Chris H0001415889-24-023588
SEC(opens sec.gov)
Jul 234
Takimoto Chris H0001415889-24-020005
SEC(opens sec.gov)
Jun 184
Takimoto Chris H0001415889-24-017500
SEC(opens sec.gov)
Mar 154
Takimoto Chris H0001415889-24-008171
SEC(opens sec.gov)
Mar 144
Takimoto Chris H0001415889-24-008056
SEC(opens sec.gov)
Dec 14
Takimoto Chris H0001209191-23-057113
SEC(opens sec.gov)
May 254
Takimoto Chris H0001209191-23-032306
SEC(opens sec.gov)
Apr 64
Takimoto Chris H0001209191-23-023703
SEC(opens sec.gov)
Mar 164
Takimoto Chris H0001209191-23-019421
SEC(opens sec.gov)
Dec 204
Takimoto Chris H0001209191-22-062262
SEC(opens sec.gov)

Companies

Address

C/O ALX ONCOLOGY HOLDINGS INC. 323 ALLERTON AVENUE

SOUTH SAN FRANCISCO, CA, 94080